Covid vaccine from Germany´s CureVac just 48% effective
By
Thursday Jul 01, 2021
FRANKFURT: Germany´s CureVac said Wednesday that final trial results showed its coronavirus vaccine had an efficacy rate of just 48 percent, far lower than those developed by mRNA rivals BioNTech/Pfizer and Moderna.
The outcome had been expected after poor interim data were released earlier this month.
The company in part blamed the unprecedented context of 15 strains circulating among the trial volunteers, as well as varying responses across age groups.
The Covid vaccines developed by Germany´s BioNTech in partnership with US giant Pfizer and by US firm Moderna based on the same novel messenger RNA technology were approved earlier on in the pandemic after showing around 95 percent efficacy.
Covid vaccine from Germany s CureVac just 48 percent effective
thelocal.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelocal.de Daily Mail and Mail on Sunday newspapers.
COVID-19 vaccine from Germany s CureVac just 48% effective
euractiv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from euractiv.com Daily Mail and Mail on Sunday newspapers.
CureVac disappoints in pivotal final trial of COVID-19 vaccine with 48 percent efficacy
wionews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wionews.com Daily Mail and Mail on Sunday newspapers.